The literature review provides us with the necessary information to draw conclusions about the impact of SGLT2 inhibitors and GLP-1 RA on renal and cardiac outcomes in both type 2 diabetes patients and non-diabetics. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.